Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Edwards Lifesciences price target raised to $133 from $123 at Piper Sandler » 19:16
12/08/21
12/08
19:16
12/08/21
19:16
EW

Edwards Lifesciences

$119.46 /

+3.99 (+3.46%)

Piper Sandler analyst…

Piper Sandler analyst Adam Maeder raised the firm's price target on Edwards Lifesciences to $133 from $123 and keeps an Overweight rating on the shares. The analyst said the company's guidance for FY21 and FY22, as well as its pipeline updates, lay the foundation for long-term growth. Maeder added that he continues to view Edwards as a differentiated large-cap medtech growth name with a "compelling" and durable financial profile.

ShowHide Related Items >><<
EW Edwards Lifesciences
$119.46 /

+3.99 (+3.46%)

EW Edwards Lifesciences
$119.46 /

+3.99 (+3.46%)

12/06/21 Wells Fargo
Wells Fargo upgrades Edwards Lifesciences to Overweight on pipeline catalysts
12/06/21 Wells Fargo
Edwards Lifesciences upgraded to Overweight from Equal Weight at Wells Fargo
11/30/21 Piper Sandler
Edwards Lifesciences positioned as 'beat-and-raise story,' says Piper Sandler
10/29/21 Jefferies
Edwards Lifesciences price target raised to $135 from $130 at Jefferies
EW Edwards Lifesciences
$119.46 /

+3.99 (+3.46%)

EW Edwards Lifesciences
$119.46 /

+3.99 (+3.46%)

EW Edwards Lifesciences
$119.46 /

+3.99 (+3.46%)

Conference/Events
Edwards Lifesciences to host investor meeting » 11:25
12/08/21
12/08
11:25
12/08/21
11:25
EW

Edwards Lifesciences

$118.68 /

+3.21 (+2.78%)

Investor meeting to be…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EW Edwards Lifesciences
$118.68 /

+3.21 (+2.78%)

EW Edwards Lifesciences
$118.68 /

+3.21 (+2.78%)

12/06/21 Wells Fargo
Wells Fargo upgrades Edwards Lifesciences to Overweight on pipeline catalysts
12/06/21 Wells Fargo
Edwards Lifesciences upgraded to Overweight from Equal Weight at Wells Fargo
11/30/21 Piper Sandler
Edwards Lifesciences positioned as 'beat-and-raise story,' says Piper Sandler
10/29/21 Jefferies
Edwards Lifesciences price target raised to $135 from $130 at Jefferies
EW Edwards Lifesciences
$118.68 /

+3.21 (+2.78%)

EW Edwards Lifesciences
$118.68 /

+3.21 (+2.78%)

EW Edwards Lifesciences
$118.68 /

+3.21 (+2.78%)

Hot Stocks
Edwards Lifesciences sees FY22 free cash flow $1.2B-$1.5B  09:22
12/08/21
12/08
09:22
12/08/21
09:22
EW

Edwards Lifesciences

$115.51 /

+3.55 (+3.17%)

 
ShowHide Related Items >><<
EW Edwards Lifesciences
$115.51 /

+3.55 (+3.17%)

EW Edwards Lifesciences
$115.51 /

+3.55 (+3.17%)

12/06/21 Wells Fargo
Wells Fargo upgrades Edwards Lifesciences to Overweight on pipeline catalysts
12/06/21 Wells Fargo
Edwards Lifesciences upgraded to Overweight from Equal Weight at Wells Fargo
11/30/21 Piper Sandler
Edwards Lifesciences positioned as 'beat-and-raise story,' says Piper Sandler
10/29/21 Jefferies
Edwards Lifesciences price target raised to $135 from $130 at Jefferies
EW Edwards Lifesciences
$115.51 /

+3.55 (+3.17%)

EW Edwards Lifesciences
$115.51 /

+3.55 (+3.17%)

EW Edwards Lifesciences
$115.51 /

+3.55 (+3.17%)

Hot Stocks
Edwards Lifesciences sees 2022 TAVR sales $3.7B-$4B; underlying growth 12%-15% » 09:17
12/08/21
12/08
09:17
12/08/21
09:17
EW

Edwards Lifesciences

$115.51 /

+3.55 (+3.17%)

Projecting 2022 TMTT…

Projecting 2022 TMTT sales of $140M-$170M. Focused long-term growth investments with 2022 R&D planned at 17%-18% of sales; Meaningful progress on 7 pivotal trials across TAVR and TMTT; Global market opportunity across 4 product groups projected to double to nearly $20B by 2028.

ShowHide Related Items >><<
EW Edwards Lifesciences
$115.51 /

+3.55 (+3.17%)

EW Edwards Lifesciences
$115.51 /

+3.55 (+3.17%)

12/06/21 Wells Fargo
Wells Fargo upgrades Edwards Lifesciences to Overweight on pipeline catalysts
12/06/21 Wells Fargo
Edwards Lifesciences upgraded to Overweight from Equal Weight at Wells Fargo
11/30/21 Piper Sandler
Edwards Lifesciences positioned as 'beat-and-raise story,' says Piper Sandler
10/29/21 Jefferies
Edwards Lifesciences price target raised to $135 from $130 at Jefferies
EW Edwards Lifesciences
$115.51 /

+3.55 (+3.17%)

EW Edwards Lifesciences
$115.51 /

+3.55 (+3.17%)

EW Edwards Lifesciences
$115.51 /

+3.55 (+3.17%)

Earnings
Edwards Lifesciences sees FY22 adjusted EPS $2.50-$2.65, consensus $2.58 » 09:12
12/08/21
12/08
09:12
12/08/21
09:12
EW

Edwards Lifesciences

$115.51 /

+3.55 (+3.17%)

Sees FY22 revenue…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EW Edwards Lifesciences
$115.51 /

+3.55 (+3.17%)

EW Edwards Lifesciences
$115.51 /

+3.55 (+3.17%)

12/06/21 Wells Fargo
Wells Fargo upgrades Edwards Lifesciences to Overweight on pipeline catalysts
12/06/21 Wells Fargo
Edwards Lifesciences upgraded to Overweight from Equal Weight at Wells Fargo
11/30/21 Piper Sandler
Edwards Lifesciences positioned as 'beat-and-raise story,' says Piper Sandler
10/29/21 Jefferies
Edwards Lifesciences price target raised to $135 from $130 at Jefferies
EW Edwards Lifesciences
$115.51 /

+3.55 (+3.17%)

EW Edwards Lifesciences
$115.51 /

+3.55 (+3.17%)

EW Edwards Lifesciences
$115.51 /

+3.55 (+3.17%)

Earnings
Edwards Lifesciences backs FY21 adjusted EPS view at high end of $2.07-$2.27 » 09:11
12/08/21
12/08
09:11
12/08/21
09:11
EW

Edwards Lifesciences

$115.51 /

+3.55 (+3.17%)

FY21 EPS consensus $2.26.…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EW Edwards Lifesciences
$115.51 /

+3.55 (+3.17%)

EW Edwards Lifesciences
$115.51 /

+3.55 (+3.17%)

12/06/21 Wells Fargo
Wells Fargo upgrades Edwards Lifesciences to Overweight on pipeline catalysts
12/06/21 Wells Fargo
Edwards Lifesciences upgraded to Overweight from Equal Weight at Wells Fargo
11/30/21 Piper Sandler
Edwards Lifesciences positioned as 'beat-and-raise story,' says Piper Sandler
10/29/21 Jefferies
Edwards Lifesciences price target raised to $135 from $130 at Jefferies
EW Edwards Lifesciences
$115.51 /

+3.55 (+3.17%)

EW Edwards Lifesciences
$115.51 /

+3.55 (+3.17%)

EW Edwards Lifesciences
$115.51 /

+3.55 (+3.17%)

Conference/Events
Edwards Lifesciences to host investor meeting » 04:55
12/08/21
12/08
04:55
12/08/21
04:55
EW

Edwards Lifesciences

$115.51 /

+3.55 (+3.17%)

Investor meeting to be…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
EW Edwards Lifesciences
$115.51 /

+3.55 (+3.17%)

EW Edwards Lifesciences
$115.51 /

+3.55 (+3.17%)

12/06/21 Wells Fargo
Wells Fargo upgrades Edwards Lifesciences to Overweight on pipeline catalysts
12/06/21 Wells Fargo
Edwards Lifesciences upgraded to Overweight from Equal Weight at Wells Fargo
11/30/21 Piper Sandler
Edwards Lifesciences positioned as 'beat-and-raise story,' says Piper Sandler
10/29/21 Jefferies
Edwards Lifesciences price target raised to $135 from $130 at Jefferies
EW Edwards Lifesciences
$115.51 /

+3.55 (+3.17%)

EW Edwards Lifesciences
$115.51 /

+3.55 (+3.17%)

EW Edwards Lifesciences
$115.51 /

+3.55 (+3.17%)

Monday
Upgrade
Wells Fargo upgrades Edwards Lifesciences to Overweight on pipeline catalysts » 07:24
12/06/21
12/06
07:24
12/06/21
07:24
EW

Edwards Lifesciences

$108.54 /

-1.23 (-1.12%)

As previously reported,…

As previously reported, Wells Fargo analyst Larry Biegelsen upgraded Edwards Lifesciences to Overweight from Equal Weight with a $126 price target. The analyst sees a long runway for transcatheter aortic valve replacement growth beyond low risk and expects the pivotal U.S. trial for the company's Pascal transcatheter mitral valve repair device to be positive when it's presented in 2022, leading to approval by late 2022/early 2023. Biegelsen is "particularly optimistic" about the EARLY-TAVR trial in asymptomatic aortic stenosis patients based on the positive results from a similar but smaller trial in November. EARLY-TAVR has the potential to almost double the current market for TAVR devices, and he thinks EARLY-TAVR could read out before all patients reach their minimum of two-year follow-up period. In addition to the asymptomatic opportunity, the analyst sees a number of other incremental opportunities for TAVR.

ShowHide Related Items >><<
EW Edwards Lifesciences
$108.54 /

-1.23 (-1.12%)

EW Edwards Lifesciences
$108.54 /

-1.23 (-1.12%)

12/06/21 Wells Fargo
Edwards Lifesciences upgraded to Overweight from Equal Weight at Wells Fargo
11/30/21 Piper Sandler
Edwards Lifesciences positioned as 'beat-and-raise story,' says Piper Sandler
10/29/21 Jefferies
Edwards Lifesciences price target raised to $135 from $130 at Jefferies
10/28/21 Wells Fargo
Edwards Lifesciences price target raised to $126 from $115 at Wells Fargo
EW Edwards Lifesciences
$108.54 /

-1.23 (-1.12%)

EW Edwards Lifesciences
$108.54 /

-1.23 (-1.12%)

EW Edwards Lifesciences
$108.54 /

-1.23 (-1.12%)

Upgrade
Edwards Lifesciences upgraded to Overweight from Equal Weight at Wells Fargo » 04:50
12/06/21
12/06
04:50
12/06/21
04:50
EW

Edwards Lifesciences

$108.54 /

-1.23 (-1.12%)

Wells Fargo analyst Larry…

Wells Fargo analyst Larry Biegelsen upgraded Edwards Lifesciences to Overweight from Equal Weight with a $126 price target.

ShowHide Related Items >><<
EW Edwards Lifesciences
$108.54 /

-1.23 (-1.12%)

EW Edwards Lifesciences
$108.54 /

-1.23 (-1.12%)

11/30/21 Piper Sandler
Edwards Lifesciences positioned as 'beat-and-raise story,' says Piper Sandler
10/29/21 Jefferies
Edwards Lifesciences price target raised to $135 from $130 at Jefferies
10/28/21 Wells Fargo
Edwards Lifesciences price target raised to $126 from $115 at Wells Fargo
10/28/21 Citi
Edwards Lifesciences price target raised to $120 from $113 at Citi
EW Edwards Lifesciences
$108.54 /

-1.23 (-1.12%)

EW Edwards Lifesciences
$108.54 /

-1.23 (-1.12%)

EW Edwards Lifesciences
$108.54 /

-1.23 (-1.12%)

Saturday
Conference/Events
Edwards Lifesciences to host investor meeting » 17:32
12/04/21
12/04
17:32
12/04/21
17:32
EW

Edwards Lifesciences

$108.54 /

-1.23 (-1.12%)

Investor meeting to be…

Investor meeting to be held in Irvine, CA on December 8 at 11:30 am. Webcast Link

ShowHide Related Items >><<
EW Edwards Lifesciences
$108.54 /

-1.23 (-1.12%)

EW Edwards Lifesciences
$108.54 /

-1.23 (-1.12%)

11/30/21 Piper Sandler
Edwards Lifesciences positioned as 'beat-and-raise story,' says Piper Sandler
10/29/21 Jefferies
Edwards Lifesciences price target raised to $135 from $130 at Jefferies
10/28/21 Wells Fargo
Edwards Lifesciences price target raised to $126 from $115 at Wells Fargo
10/28/21 Citi
Edwards Lifesciences price target raised to $120 from $113 at Citi
EW Edwards Lifesciences
$108.54 /

-1.23 (-1.12%)

EW Edwards Lifesciences
$108.54 /

-1.23 (-1.12%)

EW Edwards Lifesciences
$108.54 /

-1.23 (-1.12%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.